MAP2K7 and cancer: Some studies have found that (46), MEK inhibitors combined with radiotherapy can increase the expression of major histocompatibility complex class I on the surface of tumor cells, activate anti-cancer immunity in vivo, improve the ability of T cells to recognize and kill cancer cells, so as to achieve better anti-tumor effect.